medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients

Aldámiz-Echevarría T, González-García J, Von WMA , Crespo M, López-Aldeguer J, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Bellón JM, Montes M, Berenguer J

Language: English
References: 11
Page: 464-469
PDF size: 88.23 Kb.


ABSTRACT

Background and rationale for the study. We assessed the association of CD4+ T-cell counts and HIV-RNA on sustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coinfected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between 2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results. We studied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reduced odds of SVR included genotype 1 or 4, HCV-RNA › 500,000 IU/mL, advanced liver fibrosis, CDC clinical category C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparison with patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio [95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57) for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclusions. Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However, this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this represents a true association of HIV-RNA on response to PR or a spurious association due to poor adherence to treatment.


REFERENCES

  1. Neukam K, Camacho A, Caruz A, Rallon N, Torres-Cornejo A, Rockstroh JK, Macias J, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012; 56: 788-94.

  2. Mira JA, Garcia-Rey S, Rivero A, de los Santos-Gil I, Lopez- Cortes LF, Giron-Gonzalez JA, Tellez F, et al. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012; 55: 1719-26.

  3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.

  4. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.

  5. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.

  6. Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, Lopez-Aldeguer J, Alvarez-Pellicer J, et al. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother 2011; 66: 2843-9.

  7. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.

  8. Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47: 36-49.

  9. Mira JA, Gutierrez-Valencia A, Gil Ide L, Merino D, Rivero A, Rios-Villegas MJ, Delgado M, et al. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009; 49: e84-e91.

  10. World Health Organization: Guidelines for the screening, care and treatment of persons with hepatitis C infection. France: World Health Organization, 2014..Available from: http://www.who.int/hiv/pub/hepatitis/hepatitis-cguidelines/ en/

  11. Pawlotsky JM, Aghemo A, Dusheiko G, Forns X, Puoti M, Sarrazin C. EASL Recommendations on Treatment of Hepatitis C April 2014. Geneva, Switzerland: EASL Office, 2014. Available from: http://www.easl.eu/_newsroom/latest-news/ easl-recommendations-on-treatment-of-hepatitis-c-2014




2020     |     www.medigraphic.com